216.35 +0.05 (0.02%)
After hours: 4:06PM EDT
|Bid||216.35 x 9200|
|Ask||216.36 x 400|
|Day's Range||215.80 - 218.05|
|52 Week Range||156.03 - 226.44|
|PE Ratio (TTM)||38.69|
|Forward Dividend & Yield||0.68 (0.32%)|
|1y Target Est||N/A|
Thermo Fisher (TMO) benefits from its acquisition of FEI, consistently adding stimulus to its analytical instruments portfolio for over a year now.
The complaint, which was filed in Boston federal court on Wednesday, alleges that Thermo Fisher violated laws barring discrimination against veterans and people with disabilities.
Despite its decent start, March ended up being another bad month for the market. The S&P 500 lost 2.7% of its value last month, defying the odds in doing so; the index gains an average of half a percent in the month that just ended.
The Zacks Analyst Blog Highlights: Amgen, FedEx, Thermo Fisher, Sherwin-Williams and Ameriprise
As of March 15, 2018, Thermo Fisher Scientific (TMO) was trading at a forward PE (price-to-earnings) ratio of 19.2x. The stock has a current PE ratio of 34.9x. For the calculation of the forward PE multiple of a company, the company’s current stock price is divided by the next 12-month earnings estimates for the company. The multiple is an estimate of the potential growth of the company over the next 12 months.
Thermo Fisher Scientific (TMO) forges ahead with initiatives to strengthen its hold in the high-potential human identification market.
Thermo Fisher Scientific Inc., a Waltham, Mass.-based biotechnology product-development company, has acquired IntegenX Inc.
Thermo Fisher Scientific offers products including analytical instruments, reagents, equipment, consumables, diagnostics and research software, and services. The company has registered steady growth over recent years mainly through partnerships, collaborations, and tuck-in acquisitions. Recently, the company has entered a number of research partnerships focused on providing solutions to treat cancer and neurodegenerative diseases. On March 9, 2018, BioDiscovery and Thermo Fisher Scientific announced their partnership for the development of an end-to-end cancer research product.
The U.S. government said on Friday it will pay for certain genetic tests for Medicare-eligible patients with advanced cancer, in a bid to help match patients with the drugs most likely to provide benefit. The Centers for Medicare & Medicaid Services (CMS) said that diagnostic laboratory tests using Next Generation Sequencing (NGS) would be covered by the government healthcare program. The National Coverage Determination (NCD) is an important step in the advance of so-called personalized medicine and follows U.S. Food and Drug Administration approvals of the tests.
On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of the new Thermo Scientific Chromeleon XTR Laboratory Management system, which was designed to manage an entire laboratory. The software has the ability to support data integrity, process adherence, and regulatory compliance. The system provides enhanced data software capabilities like sample management and data archiving as compared to the traditional CDS (chromatography data systems).
The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to the reform.